N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities

Reza Bavarsad Shahripour, Mark R Harrigan, Andrei V Alexandrov, Reza Bavarsad Shahripour, Mark R Harrigan, Andrei V Alexandrov

Abstract

Background: There is an expanding field of research investigating the benefits of medicines with multiple mechanisms of action across neurological disorders. N-acetylcysteine (NAC), widely known as an antidote to acetaminophen overdose, is now emerging as treatment of vascular and nonvascular neurological disorders. NAC as a precursor to the antioxidant glutathione modulates glutamatergic, neurotrophic, and inflammatory pathways.

Aim and discussion: Most NAC studies up to date have been carried out in animal models of various neurological disorders with only a few studies completed in humans. In psychiatry, NAC has been tested in over 20 clinical trials as an adjunctive treatment; however, this topic is beyond the scope of this review. Herein, we discuss NAC molecular, intracellular, and systemic effects, focusing on its potential applications in neurodegenerative diseases including spinocerebellar ataxia, Parkinson's disease, tardive dyskinesia, myoclonus epilepsy of the Unverricht-Lundbor type as well as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease.

Conclusion: Finally, we review the potential applications of NAC to facilitate recovery after traumatic brain injury, cerebral ischemia, and in treatment of cerebrovascular vasospasm after subarachnoid hemorrhage.

Keywords: N-acetylcysteine; neurological disorder; treatment.

Figures

Figure 1
Figure 1
Mechanism of action of N-acetylcysteine (NAC). ASC, alanine-serine-cysteine (ASC) transport system; c-GCS, c-glutamylcysteine synthetase; cys, cysteine; glu, glutamine; gly, glycine; GSH, glutathione.

References

    1. N-acetylcysteine. Altern. Med. Rev. 2000;5:467–471.
    1. Abello PA, Fidler SA, Buchman TG. Thiol reducing agents modulate induced apoptosis in porcine endothelial cells. Shock. 1994;2:79–83.
    1. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology. 2001;57:1515–1517.
    1. Adams JD, Jr, Klaidman LK, Odunze IN, Shen HC, Miller CA. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol. Chem. Neuropathol. 1991;14:213–226.
    1. Adler V, Yin Z, Tew KD, Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene. 1999;18:6104–6111.
    1. Akca T, Canbaz H, Tataroglu C, Caglikulekci M, Tamer L, Colak T, et al. The effect of N-acetylcysteine on pulmonary lipid peroxidation and tissue damage. J. Surg. Res. 2005;129:38–45.
    1. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. 1993;90:7915–7922.
    1. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J. Am. Coll. Cardiol. 2001;37:117–123.
    1. Arakawa M, Ito Y. N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum. 2007;6:308–314.
    1. Arrigo A-P. Gene expression and the thiol redox state. Free Radical Biol. Med. 1999;27:936–944.
    1. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radical Biol. Med. 1989;6:593–597.
    1. Atkuri KR, Mantovani JJ, Herzenberg LA. N-Acetylcysteine–a safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol. 2007;7:355–359.
    1. Bannai S, Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J. Membr. Biol. 1986;89:1–8.
    1. Beckman KB, Ames BN. Oxidative decay of DNA. J. Biol. Chem. 1997;272:19633–19636.
    1. Behar TN, Colton CA. Redox regulation of neuronal migration in a Down Syndrome model. Free Radical Biol. Med. 2003;35:566–575.
    1. Braak H, Rub K, Del Tredici U, Jansen Steur RA, de Vos EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 2003;24:197–211.
    1. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature. 1995;378:776–779.
    1. Cabassi A, Dumont EC, Girouard H, Bouchard JF, Lamontagne M, Le Jossec D, et al. Effects of chronic N-acetylcysteine treatment on the actions of peroxynitrite on aortic vascular reactivity in hypertensive rats. J. Hypertens. 2001;19:1233–1244.
    1. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radical Biol. Med. 2000;29:323–333.
    1. Chen G, Shi J, Hu Z, Hang C. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm. 2008;2008:716458.
    1. Clark J, Clore EL, Zheng K, Adame A, Masliah E, Simon DK. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS ONE. 2010;5:e12333.
    1. Cotgreave IA, Moldeus P. Methodologies for the analysis of reduced and oxidized N-acetylcysteine in biological systems. Biopharm. Drug Dispos. 1987;8:365–375.
    1. Cray PN, May PC, Mundy L, Elkins J. L-Glutamate toxicity in Huntington's disease fibroblasts. Biochem. Biophys. Res. Commun. 1980;95:707–714.
    1. Cuzzocrea S, Mazzon E, Costantino G, Serraino I, Caputi A, De Sarro AP. Effects of n-acetylcysteine in a rat model of ischemia and reperfusion injury. Cardiovasc. Res. 2000a;47:537–548.
    1. Cuzzocrea S, Mazzon E, Costantino G, Serraino I, Dugo L, Calabrò G, et al. Beneficial effects of N-acetylcysteine on ischaemic brain injury. Br. J. Pharmacol. 2000b;130:1219–1226.
    1. Davis W, Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J. Pharmacol. Exp. Ther. 2001;296:1–6.
    1. Dawson T, Dawson V. Protection of the brain from ischemia. Cerebrovasc. Dis. 1997;7:349–352.
    1. De Mattia G, Bravi M, Laurenti O, Cassone-Faldetta M, Proietti A, De Luca O, et al. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia. 1998;41:1392–1396.
    1. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 2011;36:78–86.
    1. Dekhuijzen P. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur. Respir. J. 2004;23:629–636.
    1. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation. 2000;102:670–676.
    1. Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. “Baltic” myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet. 1983;2:838–842.
    1. Eylar E, Rivera-Quinones C, Molina C, Baez I, Molina F, Mercado CM. N-acetylcysteine enhances T cell functions and T cell growth in culture. Int. Immunol. 1993;5:97–101.
    1. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, et al. The antioxidants α-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem. 2003;84:1173–1183.
    1. Findlay J, Weir B, Kanamaru K, Espinosa F. Arterial wall changes in cerebral vasospasm. Neurosurgery. 1989;25:736–746.
    1. Fontaine MA, Geddes JW, Banks A, Butterfield DA. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-inducedin vivo oxidative stress and striatal lesions. J. Neurochem. 2000;75:1709–1715.
    1. Frank J, Pompella A, Biesalski H. Histochemical visualization of oxidant stress. Free Radical Biol. Med. 2000;29:1096–1105.
    1. Friehs GM, Bavarsad Shahripour R, Alexandrov AV, Harrigan MR. Treatment of symptomatic cerebral vasospasm with N-acetylcysteine. J. NeuroImag. 2014 under review.
    1. Fu R, Wassif CA, Yanjanin NM, Watkins-Chow DE, Baxter LL, Incao A, et al. Efficacy of N-acetylcysteine in phenotypic suppression of mouse models of Niemann-Pick disease, type C1. Hum. Mol. Genet. 2013;22:3508–3523.
    1. Galili-Mosberg R, Gil-Ad I, Weizman A, Melamed E, Offen D. Haloperidol–induced neurotoxicity–possible implications for tardive dyskinesia. J. Neural Transm. 2000;107:479–490.
    1. Galis ZS, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells new target for antioxidant therapy? Circulation. 1998;97:2445–2453.
    1. Galle J, Heermeier K, Wanner C. Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int. 1999;56:S62–S65.
    1. Geller HM, Cheng KY, Goldsmith NK, Romero AA, Zhang AL, Morris EJ, et al. Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside. J. Neurochem. 2001;78:265–275.
    1. Gere-Paszti E, Jakus J. The effect of N-acetylcysteine on amphetaminemediateddopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography. Biomed. Chromatogr. 2009;23:658–664.
    1. Ghigliotti G, Mereto E, Eisenberg PR, Martelli A, Orsi P, Sini D, et al. N-acetyl-cysteine reduces neointimal thickening and procoagulant activity after balloon-induced injury in abdominal aortae of New Zealand white rabbits. Thromb. Haemost. 2001;85:724–729.
    1. Giustarini D, Milzani A, Dalle-Donne I, Tsikas D, Rossi R. N-Acetylcysteine ethyl ester (NACET): a novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential. Biochem. Pharmacol. 2012;84:1522–1533.
    1. Glabiński A, Tawsek N, Bartosz G. Increased generation of superoxide radicals in the blood of MS patients. Acta Neurol. Scand. 1993;88:174–177.
    1. Güney O, Erdi F, Esen H, Kiyici A, Kocaogullar Y. N-acetylcysteine prevents vasospasm after subarachnoid hemorrhage. World Neurosurg. 2010;73:42–49.
    1. Halliwell B, Gutteridge JM. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys. 1986;246:501–514.
    1. Hans VH, Kossmann T, Lenzlinger PM, Probstmeier R, Imhof H-G, Trentz O, et al. Experimental axonal injury triggers interleukin-6 mRNA, protein synthesis and release into cerebrospinal fluid. J. Cereb. Blood Flow Metab. 1999;19:184–194.
    1. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N. Engl. J. Med. 1991;324:1852–1857.
    1. Hicdonmez T, Kanter M, Tiryaki M, Parsak T, Cobanoglu S. Neuroprotective effects of N-acetylcysteine on experimental closed head trauma in rats. Neurochem. Res. 2006;31:473–481.
    1. Hoffer E, Baum Y, Nahir AM. N-Acetylcysteine enhances the action of anti-inflammatory drugs as suppressors of prostaglandin production in monocytes. Mediators Inflamm. 2002;11:321–323.
    1. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin. Pharmacokinet. 1991;20:123–134.
    1. Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Oz G, et al. N-acetylcysteine boosts brain and blood glutathione in gaucher and Parkinson diseases. Clin. Neuropharmacol. 2013;36:103–106.
    1. Hsu BG, Lee RP, Yang FL, Harn HJ, Chen HI. Post-treatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats. Life Sci. 2006;79:2010–2016.
    1. Ichiki T, Takeda K, Tokunou T, Funakoshi Y, Ito K, Iino N, et al. Reactive oxygen species-mediated homologous downregulation of angiotensin II type 1 receptor mRNA by angiotensin II. Hypertension. 2001;37:535–540.
    1. Ishige K, Tanaka M, Arakawa M, Saito H, Ito Y. Distinct nuclear factor-kappaB/Rel proteins have opposing modulatory effects in glutamate-induced cell death in HT22 cells. Neurochem. Int. 2005;47:545–555.
    1. Jenner P. Oxidative damage in neurodegenerative disease. Lancet. 1994;344:796–798.
    1. Jiang CT, Wan XH, He Y, Pan TH, Jankovic J, Le WD. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol. 2005;191:154–162.
    1. Kelly GS. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 1998;3:114–127.
    1. Kerksick C, Willoughby D. The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. J. Int. Soc. Sports Nutr. 2005;2:38–44.
    1. Khan M, Sekhon B, Jatana M, Giri S, Gilg AG, Sekhon C, et al. Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J. Neurosci. Res. 2004;76:519–527.
    1. Kim YH, Takahashi M, Suzuki E, Niki E. Apoptosis induced by hydrogen peroxide under serum deprivation and its inhibition by antisense c-jun in F-MEL cells. Biochem. Biophys. Res. Commun. 2000;271:747–752.
    1. Lander HM. An essential role for free radicals and derived species in signal transduction. FASEB J. 1997;11:118–124.
    1. Lee JS, Kypreos KE, Sonenshein GE. Synchronization of cultured vascular smooth muscle cells following reversal of quiescence induced by treatment with the antioxidant N-acetylcysteine. Exp. Cell Res. 1998;239:447–453.
    1. Lee S-L, Wang W-W, Finlay GA, Fanburg BL. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am. J. Physiol. 1999;277:L282–L291.
    1. Lehesjoki AE, Koskiniemi M. Clinical features and genetics of progressive myoclonus epilepsy of the Univerricht–Lundborg type. Ann. Med. 1998;30:474–480.
    1. Lehesjoki AE, Eldridge R, Eldridge J, Wilder BJ, de la Chapelle A. Progressive myoclonus epilepsy of Unverricht-Lundborg type: a clinical and molecular genetic study of a family from the United States with four affected sibs. Neurology. 1993;43:2384–2386.
    1. Lehmann D, Karussis D, Misrachi-Koll R, Shezen E, Ovadia H, Abramsky O. Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1994;50:35–42.
    1. Li AE, Ito H, Rovira II, Kim K-S, Takeda K, Yu Z-Y, et al. A role for reactive oxygen species in endothelial cell anoikis. Circ. Res. 1999;85:304–310.
    1. Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illness. Psychopharmacol. Bull. 1995;31:159–165.
    1. Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes F, de Jong J. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch. Neurol. 1995;52:559.
    1. Martin KR, Kari FW, Barrett JC, French JE. N-acetyl-L-cysteine simultaneously increases mitogenesis and suppresses apoptosis in mitogen-stimulated B-lymphocytes from p53 haploinsufficient Tg. AC (v-Ha-ras) mice. In Vitr. Mol. Toxicol. 2000;13:237–247.
    1. Martínez M, Martínez N, Hernández AI, Ferrándiz ML. Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci. 1999;64:1253–1257.
    1. Mass H, Pirazzi B, Gonzalez P, Collazo V, Fitzovich D, Avakian E. N-acetylcysteine diminishes injury induced by balloon angioplasty of the carotid artery in rabbits. Biochem. Biophys. Res. Commun. 1995;215:613–618.
    1. May PC, Gray PN. The mechanism of glutamate-induced degeneration of cultured Huntington's disease and control fibroblasts. J. Neurol. Sci. 1985;70:101–112.
    1. Mayer M, Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc. Natl. Acad. Sci. 1994;91:7496–7500.
    1. McLellan LI, Lewis AD, Hall DJ, Ansell JD, Wolf CR. Uptake and distribution of N-acetylcysteine in mice: tissue-specific effects on glutathione concentrations. Carcinogenesis. 1995;16:2099–2106.
    1. Meister A. Glutathione metabolism. Methods Enzymol. 1995;251:3.
    1. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 1996;19:331–338.
    1. Millea PJ. N-acetylcysteine: multiple clinical applications. Am. Fam. Physician. 2009;80:265–269.
    1. Morganti-Kossmann MC, Rancan M, Otto VI, Stahel PF, Kossmann T. Role of cerebral inflammation after traumatic brain injury: a revisited concept. Shock. 2001;16:165–177.
    1. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J. Cereb. Blood Flow Metab. 2011;31:1003–1019.
    1. Nagase M, Ando K, Nagase T, Kaname S, Sawamura T, Fujita T. Redox-sensitive regulation of lox-1 gene expression in vascular endothelium. Biochem. Biophys. Res. Commun. 2001;281:720–725.
    1. Pahl HL, Baeuerle PA. Oxygen and the control of gene expression. BioEssays. 1994;16:497–502.
    1. Pan J, Xiao Q, Sheng CY, Hong Z, Yang HQ, Wang G, et al. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem. Int. 2009;54:418–425.
    1. Pappert E, Tangney C, Goetz C, Ling Z, Lipton J, Stebbins G, et al. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients Dose-response study and correlations with plasma levels. Neurology. 1996;47:1037–1042.
    1. Rancan M, Otto VI, Hans VH, Gerlach I, Jork R, Trentz O, et al. Upregulation of ICAM-1 and MCP-1 but not of MIP-2 and sensorimotor deficit in response to traumatic axonal injury in rats. J. Neurosci. Res. 2001;63:438–446.
    1. Reilly D, Hershey L, Rivera-Calimlim L, Shoulson I. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. Adv. Neurol. 1983;37:51.
    1. Remington R, Chan A, Paskavitz J, Shea TB. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am. J. Alzheimers Dis. Other Demen. 2009;24:27–33.
    1. Reynaud E. Protein misfolding and degenerative diseases. Nat. Educ. 2010;3:28.
    1. Richman PG, Meister A. Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. J. Biol. Chem. 1975;250:1422–1426.
    1. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
    1. Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D. A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia. Clin. Neuropharmacol. 2005;28:285–288.
    1. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta. 2013;1830:4117–4129.
    1. Sandhir R, Sood A, Mehrotra A, Kamboj SS. N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease. Neurodegener. Dis. 2012;9:145–157.
    1. Sarker KP, Abeyama K, Nishi J, Nakata M, Tokioka T, Nakajima T, et al. Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor. Thromb. Haemost. 1999;82:1071–1077.
    1. Schapira A, Cooper J, Dexter D, Clark J, Jenner P, Marsden C. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990;54:823–827.
    1. Sen CK. Nutritional biochemistry of cellular glutathione. J. Nutr. Biochem. 1997;8:660–672.
    1. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 1996;10:709–720.
    1. Sen O, Caner H, Aydin MV, Ozen O, Atalay B, Altinors N, et al. The effect of mexiletine on the level of lipid peroxidation and apoptosis of endothelium following experimental subarachnoid hemorrhage. Neurol. Res. 2006;28:859–863.
    1. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 1991;325:467–472.
    1. Sheffner AL, Medler EM, Bailey KR, Gallo DG, Mueller AG, Sarett HP. Metabolic studies with acetylcysteine. Biochem. Pharmacol. 1966;15:1523–1535.
    1. Shirvan A, Shina R, Ziv I, Melamed E, Barzilai A. Induction of neuronal apoptosis by Semaphorin3A-derived peptide. Mol. Brain Res. 2000;83:81–93.
    1. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994;36:348–355.
    1. Sölen G. Radioprotective effect of N-acetylcysteine in vitro using the induction of DNA breaks as end-point. Int. J. Radiat. Biol. 1993;64:359–366.
    1. Stanislaus R, Gilg AG, Singh AK, Singh I. N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats. J. Autoimmune Dis. 2005;2:4.
    1. Su B, Mitra S, Gregg H, Flavahan S, Chotani MA, Clark KR, et al. Redox regulation of vascular smooth muscle cell differentiation. Circ. Res. 2001;89:39–46.
    1. Sunitha K, Hemshekhar M, Thushara RM, Santhosh MS, Yariswamy M, Kemparaju K, et al. N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetyl cysteine. Free Radic. Res. 2013;47:357–367.
    1. Talley AK, Dewhurst S, Perry SW, Dollard SC, Gummuluru S, Fine SM, et al. Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol. Cell. Biol. 1995;15:2359–2366.
    1. Tchantchou F, Graves M, Rogers E, Ortiz D, Shea TB. N-acteyl cysteine alleviates oxidative damage to central nervous system of ApoE-deficient mice following folate and vitamin E-deficiency. J. Alzheimers Dis. 2005;7:135–138.
    1. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 1993;328:176–183.
    1. Tsai J-C, Jain M, Hsieh C-M, Lee W-S, Yoshizumi M, Patterson C, et al. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J. Biol. Chem. 1996;271:3667–3670.
    1. Tucker S, Ahl M, Bush A, Westaway D, Huang X, Rogers JT. Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5′ untranslated region. Curr. Alzheimer Res. 2005;2:249–254.
    1. Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am. J. Physiol. 1998;274:C396–C405.
    1. Unnithan AS, Choi HJ, Titler AM, Posimo JM, Leak RK. Rescue from a two hit, high-throughput model of neurodegeneration with N-acetyl cysteine. Neurochem. Int. 2012;61:356–368.
    1. Vasdekis SN, Athanasiadis D, Lazaris A, Martikos G, Katsanos AH, Tsivgoulis G. The role of remote ischemic preconditioning in the treatment of atherosclerotic diseases. Brain Behav. 2013;3:606–616. doi: .
    1. Watson WA, McKinney PE. Activated charcoal and acetylcysteine absorption: issues in interpreting pharmacokinetic data. DICP. 1991;25:1081–1084.
    1. Wolberger C. Combinatorial transcription factors. Curr. Opin. Genet. Dev. 1998;8:552–559.
    1. Woods C, Taylor A. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q. J. Med. 1992;82:169–179.
    1. Xiong Y, Peterson P, Lee C. Effect of N-acetylcysteine on mitochondrial function following traumatic brain injury in rats. J. Neurotrauma. 1999;16:1067–1082.
    1. Xu X-P, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999;99:993–998.
    1. Yan CYI, Greene LA. Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway. J. Neurosci. 1998;18:4042–4049.
    1. Yan Z, Subbaramaiah K, Camilli T, Zhang F, Tanabe T, McCaffrey TA, et al. Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-kappaB. J. Biol. Chem. 2000;275:4949–4955.
    1. Yang GQ, Chen JS, Wen ZM, Ge KY, Zhu LZ, Chen XC, et al. The role of selenium in Keshan disease. Adv. Nutr. Res. 1984;6:203–231.
    1. Yi J-H, Hoover R, McIntosh TK, Hazell AS. Early, transient increase in complexin I and complexin II in the cerebral cortex following traumatic brain injury is attenuated by N-acetylcysteine. J. Neurotrauma. 2006;23:86–96.
    1. Yu B. Cellular defenses against damage from reactive oxygen species. Physiol. Rev. 1994;74:139–162.
    1. Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. Pharmacother. 1988;42:513–519.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel